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Epidemiology of echinocandin resistance in Candida
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Abstract
Echinocandins are the newest antifungal agents approved for use in treating Candida infections in 
the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall 
production and lead to Candida cell death. There is no intrinsic resistance to echinocandins among 
Candida species, and isolates from historic collections archived before the release of the 
echinocandins show no resistance. Resistance to the echinocandins remains low among most 
Candida species and ranges overall from 0–1%. Among isolates of Candida glabrata, the 
proportion of resistant isolates is higher and has been reported to be as high as 13.5% in at least 
one hospital. Antifungal resistance is due to specific amino acid mutations in the Fksp subunit(s) 
of the 1,3-β-D-glucan synthase protein which are localized to one of two hotspots. These 
mutations are being recognized in isolates from patients who have failed echinocandin therapy, 
and often lead to a poor outcome. While the future looks bright for the echinocandins against most 
Candida species, C. glabrata remains a species of concern and resistance rates of C. glabrata to the 
echinocandins should be monitored closely.
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Introduction
In terms of therapy to treat infection, the antifungal drugs are the relative ‘new kid on the 
block’. The polyenes were introduced in the 1950s and were the lone weapon in the arsenal 
until the 1990s when the first azole antifungal was introduced into clinical practice. The first 
echinocandin, Echinocandin B, was isolated in 1974 and was soon discovered to have 
antifungal properties [1]. However, the hemolytic properties of natural echinocandins 
prevented them from being viable candidates for human use, and it wasn’t until the approval 
of the semisynthetic echinocandin, caspofungin, by the US Food and Drug Administration in 
2001 that echinocandins were introduced into clinical practice.
Echinocandins, caspofungin, micafungin, and anidulafungin, act through noncompetitive 
inhibition of 1,3-β-D-glucan synthase, the enzyme responsible for the production of 1,3-β-
D-glucan, a component of the cell wall in many species of fungus [2, 3]. The ability of an 
antifungal to target the fungal cell wall is unique to echinocandins. Unlike amphotericin B, 
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which interacts with the sterols in both human and fungal cell membranes, use of 
echinocandins poses a much lower risk of side effects caused by incidental action of drug 
against the host’s own cells. This capacity is particularly desirable because of the presence 
of cell walls in fungal but not in animal cells. Additionally, their distinct mechanism of 
action allows echinocandins to be used against isolates that have already developed 
resistance to cell membrane active antifungals. In Candida species, this disruption of the cell 
wall is fungicidal, leading to cell lysis via osmotic instability [3].
Echinocandins are only effective against fungal species with cell walls that contain abundant 
1,3-β-D-glucan, which precludes their use against Fusarium, the Mucormycetes and 
Trichosporon. Although Cryptococcus species have 1,3-β-D-glucan, they remain resistant to 
the echinocandins [4]. In the United States and the European Union, this drug class is 
primarily approved for use against candidemia, esophageal candidiasis, and various forms of 
invasive candidiasis. Additionally, micafungin can be used as prophylaxis against Candida in 
hematopoietic stem cell transplant patients, and caspofungin is approved as treatment against 
invasive aspergillosis that is not responsive to other antifungals and for empiric treatment in 
febrile neutropenic patients.
Echinocandin Resistance
The primary mechanism of echinocandin resistance that has emerged since the introduction 
of the drug class into clinical practice is mutations in FKS1, and additionally in C. glabrata, 
FKS2, genes that encode subunits of 1,3-β-D-glucan synthase. These mutations, first 
described in Candida isolates in 2005 [5], occur in one of two areas, hot spot 1, located at 
amino acids 641-649 in Candida albicans [6], and hot spot 2, located at amino acids 
1345-1365 [7]. Hot spot mutations have been identified in C. albicans, C. glabrata, C. 
parapsilosis, C. tropicalis, C. krusei, C. dubliniensis, and, C. guilliermondii [7, 8]. In two 
studies of C. glabrata, the presence of FKS mutations was significantly associated with 
treatment failure [9, 10]. The nature of the interaction between echinocandins and FKS1 has 
not been elucidated, so the mechanisms by which these substitutions lead to reduced 
susceptibility are unclear. It has been demonstrated, however, that substitutions at different 
amino acids, even within the same hotspots, can have different impacts on resistance profiles 
in terms of which echinocandins are effected, and the extent of the decrease in susceptibility 
[11, 12]. Furthermore, more than one of these mutations can occur in the same isolate, 
producing a less susceptible phenotype than would result from either mutation singularly 
[13, 12].
Beyond FKS mutations, other mechanisms have been suggested to cause resistance to 
echinocandins. One of these is the increase of cell wall chitin content to compensate for the 
1,3-β-D-glucan depletion caused by echinocandin treatment. C. albicans has been 
demonstrated to have higher chitin content following in vitro treatment with echinocandins, 
as has C. tropicalis, some isolates of C. parapsilosis, C. guilliermondii, and, more rarely, C. 
krusei [14]. Increased chitin content was also found in a lab strain of C. glabrata treated with 
caspofungin [15], but, in a separate study, it was not found in several clinical C. glabrata 
strains grown with caspofungin at each isolate’s IC50 [14]. Multiple studies have correlated 
the induction of increased chitin content with decreased susceptibility to echinocandins in 
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vitro and in vivo [14, 16]. However, these cells with induced high chitin content have also 
been shown to be less virulent, and appear to be selected against in the absence of 
echinocandin [16], raising doubts as to their clinical viability. Nonetheless, there has been at 
least one report of a patient infected with a caspofungin-resistant C. albicans isolate with 
chitin levels four times greater than those of a sensitive reference strain, in addition to an 
FKS1 hot spot 1 mutation [17]. While the extent to which the isolate’s chitin levels 
contributed to its resistance is unclear, the case does demonstrate that it is possible for a 
strain with elevated chitin levels to cause a successful infection.
Interestingly, it has been suggested that increased chitin content may in fact precipitate FKS 
mutations. In a mouse model of infection, several isolates of a C. albicans strain that had 
been induced to possess increased chitin through growth with Ca2+ and calcofluor white 
were found to possess FKS1 hot spot 1 mutations, even if the mice they infected had not 
been treated with echinocandins. In contrast, none of the normal-chitin parental strains 
injected into mice contained any hot spot mutations [16]. It is possible that induction of the 
pathway that is responsible for increasing chitin content is also involved in increasing the 
likelihood of mutations in FKS1. At present, it is unclear what cellular changes allow some 
Candida species or strains within species to have a higher chitin content in the presence of 
echinocandins than others.
Finally, the intracellular buildup of long-chain bases dihydrosphingosine and 
phytosphingosine, both intermediates in the sphingolipid biosynthesis pathway, has been 
proposed as the mechanism of a caspofungin reduced susceptibility, micafungin increased 
susceptibility (“CRS-MIS”) profile observed in C. glabrata in both laboratory strains with 
induced caspofungin resistance and clinical strains [18, 19]. This phenotype was found to be 
induced by mutations to one of several enzymes involved in sphingolipid biosynthesis. The 
resulting excess of long-chain bases in the cell membrane has been hypothesized to alter the 
binding of echinocandins to Fks1p and Fks2p, weakening the interaction with caspofungin, 
while strengthening that with micafungin, based on the chemistry of the two echinocandins’ 
tails [19]. While this “CRS-MIS” profile and its associated mutations have been observed in 
clinical isolates, there has been no research into whether the MIC effects are maintained in 
vivo. If they are, identifying isolates in which this phenomenon is active could inform 
patient treatment, preventing treatment escalation to amphotericin B in caspofungin-resistant 
isolates that would respond to micafungin.
Several species of Candida are of particular concern because of high in vitro MIC values to 
the echinocandins. C. parapsilosis has an intrinsic variation in its FKS sequence that 
coincides with a hot spot mutation [20], and the mechanisms of C. lusitaniae and C. 
guilliermondii may be similar [21, 22]. These appear to render them less susceptible to 
echinocandins in vitro, and the extent to which this affects the efficacy of clinical 
echinocandin treatment is not yet fully understood. While C. glabrata does not possess 
intrinsic reduced susceptibility to echinocandins, it is also a species of concern for the 
development of drug resistance. Data suggest that rates of echinocandin resistance are 
greater in C. glabrata than in most other intrinsically susceptible species of Candida [23, 12, 
24–26], and it has been hypothesized that C. glabrata’s haploidy and genomic plasticity 
allows it to develop and strongly express resistance mechanisms more quickly than other 
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Candida species [24, 12, 27]. This is particularly worrisome given that C. glabrata has 
reduced sensitivity to azoles, and now has echinocandins as its recommended first line 
treatment.
Epidemiology
Changes in the rates of echinocandin resistance are difficult both to ascertain and to 
interpret. One major problem in tracking the levels of echinocandin resistance and the 
temporal and geographic changes is that the available published data have been sorted 
according to several different sets of clinical breakpoints, including the current, species-
specific Clinical and Laboratory Standards Institute (CLSI) breakpoints [28], the 2008 CLSI 
breakpoints [29], and the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) breakpoints [30], none of which are directly comparable to one another. While 
CLSI and EUCAST antifungal susceptibility testing methods have generally shown high 
categorical agreement between wild type and non-wild type isolates as judged by 
epidemiological cutoff values for anidulafungin and micafungin when applied to the major 
Candida species [31], it is unclear whether the same is true of susceptibility according to 
their respective breakpoints. Additionally, the fact that many publications describing rates of 
echinocandin resistance in the early to mid-2000s defined resistance according to the 
original, non-species-specific CLSI breakpoints has rendered much of this early data 
difficult to compare to current numbers, making it harder to determine how resistance to 
echinocandins has emerged since their introduction into practice. It should also be noted that 
while there are always questions as to the consistency of antifungal susceptibility results 
between testing sites, caspofungin MICs are notoriously variable, and there is some doubt as 
to whether they can be relied upon at all [32].
Beyond the question of the consistency of antifungal susceptibility testing results and 
definitions from laboratory to laboratory and study to study, it is currently unclear how in 
vitro echinocandin resistance should be understood as an indicator of clinical resistance and 
treatment failure. Alexander and coworkers [25] found that every C. glabrata isolate with an 
echinocandin-resistant MIC that caused a treatment failure also contained an FKS mutation. 
They concluded that the question lies in whether in vitro resistance “serve[s] as a sensitive 
but nonspecific phenotypic screen for the presence of clinically significant FKS mutations,” 
or if elevated echinocandin MICs are independently predictive of an FKS mutation. The 
former theory was supported in one study where the only independent risk factor for 
echinocandin treatment failure against invasive C. glabrata was the presence of an FKS 
mutation [33]. However, another study of C. glabrata candidemia found that the caspofungin 
MIC was effective in predicting which FKS mutants would cause treatment failure, 
reaffirming the usefulness of in vitro susceptibility data as more than a proxy [34]. The same 
study identified prior echinocandin exposure, but neither MIC nor FKS mutations, as an 
independent risk factor for treatment failure, suggesting that there may indeed be other 
clinically relevant mechanisms of resistance that such exposure could be selecting for 
beyond just FKS mutations.
Rates of echinocandin resistance as defined by MIC value in Candida vary by species, 
region, institution, and patient population. Among C. albicans, resistance tends to be very 
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low. SENTRY, a surveillance study including invasive Candida from North America, 
Europe, Latin America and Asia-Pacific in 2010 and 2011, found resistant and intermediate 
rates in this species to be 0.0% and 0.4% to anidulafungin, 0.2% and 0.4% to caspofungin, 
and 0.1% and 0.3% to micafungin, respectively [26]. In the United States, a study of 
candidemia from hospitals in Atlanta and Baltimore found 0.3% resistance to anidulafungin, 
0.5% resistance to caspofungin, and 0.3% resistance to micafungin [35]. C. parapsilosis also 
shows generally low levels of echinocandin resistance, with SENTRY capturing resistance 
rates of 0.5%, 0.0%, and 0.0%, and Atlanta and Baltimore-based surveillance finding 0.0%, 
0.3%, and 0.0% to anidulafungin, caspofungin, and micafungin, respectively.
While still fairly low, the rates of resistance to C. glabrata are noticeably higher than those of 
the other Candida species. SENTRY surveillance in 2010 & 2011 found that rates of 
resistant and intermediate isolates were 1.8% and 4.6%, 1.6% and 2.5%, and 1.2% and 0.9% 
for anidulafungin, caspofungin, and micafungin, respectively. These rates reveal 
considerable geographic variation, with no resistance in Latin America, equivalent resistance 
rates in Europe and North America (anidulafungin, 1.7% and 1.6%, caspofungin, 1.7% and 
1.6%, and micafungin, 1.1% and 1.3% in Europe and North America, respectively), and 
higher rates in Asia-Pacific (anidulafungin: 3.8%, caspofungin: 1.9%, and micafungin 1.9%)
[26]. The 2008–2011 candidemia surveillance in Atlanta and Baltimore captured 2.7%, 2.4% 
and 2.7% resistance to anidulafungin, caspofungin, and micafungin, respectively, with rates 
slightly higher in Atlanta than Baltimore (2.5–3.1% versus 2.3–2.5% resistance to the three 
drugs). It should be noted that C. glabrata resistance rates in some individual institutions 
have been reported to be much higher, as with one eastern US hospital, which reported 
12.5% resistance to anidulafungin and micafungin, and 13.5% resistance to caspofungin in 
2009 and 2010 [25].
There is considerable evidence that exposure to echinocandins predisposes patients to 
developing echinocandin-resistant Candida. This has been identified as an independent 
predictor of the presence of an FKS mutation and echinocandin treatment failure in C. 
glabrata candidemia cases [34, 25], and exposure to caspofungin within 30 days has been 
found to be an independent risk factor for blood stream infection with a Candida isolate with 
reduced caspofungin susceptibility in multiple studies [36, 37]. Epidemiological studies of 
drug resistance tend to include just the incident isolate of Candida infection. Many studies 
will not capture the isolates that develop echinocandin resistance over the course of 
treatment [35, 38], isolates which have been described in multiple publications [39, 40]. It is 
therefore possible that current estimates of echinocandin resistance rates do not entirely 
encompass the population of patients affected by these reduced-susceptibility isolates.
There is evidence that rates of echinocandin resistance are rising, though the extent to which 
this is true seems to vary greatly by location. Several surveillance studies have compared 
past and recent rates of resistance, frequently revealing an upward drift over many years. 
This may be seen very slightly with C. albicans, as in one global surveillance study that 
found rates of non-susceptibility (resistant + intermediate) increase from <0.1%, 0% and 0% 
in 2003–2007 to 0.4%, 0.6% and 0.4% in 2010–2011 for anidulafungin, caspofungin, and 
micafungin, respectively [26]. However, it is found far more dramatically in C. glabrata, the 
non-susceptibility rates of which climbed from 2.8%, 1.5% and 0.9% to 6.4%, 4.1% and 
Grossman et al. Page 5













2.1% for the same drugs over the same time period [26]. A particularly extreme example of 
this is the study from the eastern US hospital cited above, which monitored C. glabrata 
echinocandin resistance from 2001 to 2010. During the first six years of the study period, 
resistance to each echinocandin ranged from ~1.7% to ~5.0% during each two year period, 
after which it veered sharply upwards to ~9.5%-10.5 for each drug in 2007–2008, and them 
~12.5%–13.5% in 2009–2010 [25]. Of course, there are also institutions and areas that do 
not seem to be experiencing the emergence of echinocandin resistance, as with a Spanish 
institution which found no echinocandin resistance in C. glabrata or C. parapsilosis from 
2007 through 2013 (according to EUCAST antifungal testing methods and breakpoints) 
[41], or the Latin American laboratories contributing isolates to the global SENTRY 
surveillance program, which identified no C. albicans, C. glabrata, C. parapsilosis, C. 
tropicalis, or C. krusei isolates resistant to anidulafungin or micafungin in 2008 and 2009 
(isolates were not tested for susceptibility to caspofungin in this time range) [24], and no 
isolates of these species resistant to any of the echinocandins, with the exception of a single 
anidulafungin-resistant C. parapsilosis isolate among the 104 collected [26].
The other factors contributing to the overall rise of echinocandin resistance among Candida 
isolates are the downward trend in relative C. albicans prevalence, and corresponding 
upward trend in C. glabrata prevalence. This rise in C. glabrata has been noted by many 
studies [35, 42, 43, 38, 44], and has been attributed to the widespread use of fluconazole, to 
which C. glabrata has intrinsically reduced susceptibility. Given that C. glabrata has shown 
itself more likely to develop echinocandin resistance, its increasing prevalence in the patient 
population increases the likelihood of a person with candidemia having a strain with reduced 
susceptibility.
There are several patient characteristics that have been found to predispose infecting 
Candida isolates to reduced echinocandin susceptibility. Not surprisingly, limited global 
surveillance has found nosocomial C. albicans and C. glabrata candidemia isolates to 
possess more echinocandin resistance than community-acquired isolates, though C. albicans 
resistance rates were still very low in nosocomial cases [45]. Resistance also seems to be 
associated with younger age, as global surveillance found the highest rates of C. glabrata 
echinocandin resistance in patients ages 20–39 (16.7% to each echinocandin), followed by 
those ages 40–59 (7.0–4.2%, by drug), with little to no resistance in the older age groups 
[46]. In this study, there were only 5 C. glabrata isolates from patients 0–19 years old, 
among which there was no resistance, but another study of Paris-area hospitals found age 
less than 15 years to be an independent risk factor for candidemia with reduced 
echinocandin susceptibility [37].
Gastrointestinal (GI) disorders and recent GI surgery have both been significantly associated 
with infection with an isolate containing an FKS mutation. Each has also been associated 
with echinocandin treatment failure, the latter in univariate analysis only, and the former in 
multivariate analysis [34, 33]. FKS mutations have also been found more frequently in solid 
organ transplant patients with C. glabrata candidemia [25]. Additionally, a French study 
found that patients with hematological malignancy were significantly more likely to have 
recent exposure to caspofungin, suggesting that they might also be at elevated risk for 
developing echinocandin-resistant infections [37]. This conclusion is supported by the fact 
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that half of FKS mutants collected by the French National Reference Center for Mycoses 
and Antifungals were from patients with hematological malignancy [40]. It is important to 
note that there is very little data from broad surveillance studies on the medical conditions 
that predispose patients to developing echinocandin-resistant infections, so much of this data 
comes from research specific to single institutions or regions. Knowing how widely 
antifungal prescribing practices can vary, it is unknown whether these findings are 
generalizable to a larger patient population.
Given that C. glabrata demonstrates an intrinsically reduced susceptibility to fluconazole, in 
addition to an apparent predisposition for the development of echinocandin resistance, there 
is a growing concern that multidrug resistant C. glabrata will emerge as a considerable 
clinical problem. A study combining 2006–2010 SENTRY global surveillance and 2008–
2010 CDC Atlanta and Baltimore-based surveillance from found that 9.7% of C. glabrata 
isolates were resistant to fluconazole. Of these, 11.1% (accounting for 1.1% of all C. 
glabrata) were resistant to at least one echinocandin and all contained an FKS mutation [24]. 
When comparing this data to echinocandin resistance among fluconazole-resistant C. 
glabrata collected from 2001–2004, the authors saw a sharp increase, with resistance to each 
echinocandin rising from 0% in the first time period to 8.0–9.3% in the second time period. 
A study of C. glabrata candidemia isolates from four US cities found that 14.8% of 
fluconazole-resistant isolates were resistant to at least one echinocandin, accounting for 
1.5% of all isolates [12]. In a study of C. glabrata candidemia isolates from 2001–2010, 
14.1% of fluconazole-resistant isolates were resistant to at least one echinocandin (3.5% of 
all isolates), and 10.3% were resistant to all three (2.5% of all isolates) [25]. Interestingly, in 
this study, prior patient exposure to echinocandin therapy predicted not just echinocandin 
resistance, but also fluconazole resistance, most likely because echinocandin treatment was 
more frequently selected for patients who had already been exposed to fluconazole or whose 
infective agent was suspected to have reduced susceptibility to this drug. Multidrug resistant 
profiles have also been found in other species of Candida, but these incidents are far less 
frequent, as with the single echinocandin and fluconazole-resistant C. albicans found in 
Baltimore between 2008 and 2011, accounting for 0.26% of all C. albicans bloodstream 
isolates [35].
Conclusions
There are limited antifungal agents available to treat fungal infections. The development of 
resistance to echinocandins in Candida is a serious threat to our ability to manage these 
infections. Echinocandins are the empiric treatment of choice for candidemia, but it is 
essential that triazoles be used as soon as species or appropriate susceptibility of the 
infective agent can be determined. This step down therapy is one important step in 
appropriate stewardship of the echinocandins. Although MDR Candida infections are still 
relatively uncommon, the emergence of these infections demonstrates the need for action 
now to improve stewardship and to continue to monitor for the development of resistance, as 
well as to study acquisition and transmission of resistance. It is imperative that we focus on 
antifungal resistance now before losing the ability to use these important drugs.
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